Nitric oxide (NO) plays a key role in vascular homeostasis and is produced by endothelial NO synthase (eNOS), encoded by NOS3 gene. We previously reported the genetic association between NOS3 rs753482-A.C polymorphism on intron 19 and coronary artery disease (CAD). In the attempt of conferring functional implication to the rs753482-A.C polymorphism, we investigated its influence on transcript maturation.
Introduction
The volatile molecule nitric oxide (NO) is produced in humans by specialized enzymes, neuronal, inducible, and endothelial NO synthases (eNOS). All these are multidomain enzymes consisting of an N-terminal oxygenase domain with binding sites for haem, L-arginine, and tetrahydrobiopterin, and a reductase domain containing binding sites for FMN, FAD, NADPH, and calmodulin (CaM). 1, 2 Endothelial NO represents a major second messenger for a plethora of physiological processes and is a key regulator of vascular homeostasis. In particular, NO is important in regulating the vascular tone and blood flow by inhibiting smooth muscle contraction and platelet aggregation. 3, 4 Endothelial NO is also an important atheroprotective mediator; indeed, acquired defect of NO generation causes endothelial dysfunction and contributes to the development of atherosclerosis, 5 as well as reduction in basal NO release may predispose to hypertension, thrombosis, vasospasm, and atherosclerosis. 2, 6 Several studies investigating associations between NOS3 polymorphisms and vascular diseases have been reported in patients, 7 -10 together with NOS3 null mouse showing increased susceptibility to develop atherosclerosis. 11 We previously reported the genetic association of two cis-variants of the NOS3 gene, Glu298Asp rs1799983G.T and rs753482-A.C with Type 2 diabetes (T2D) and metabolic syndrome. 12 Both minor alleles were consistently enriched in T2D patients suggesting † These authors contributed equally.
a functional association between NOS3 variants and T2D; moreover, healthy carriers of the disease-associated haplotype displayed the typical features of metabolic syndrome, including insulin resistance, hyperinsulinaemia, and increased fasting NO levels. 12 In addition, coronary artery disease (CAD) and restenosis after coronary stent implantation were associated with the same NOS3 variants with a specific phenotype characterized by elevated basal NO levels, insensitivity to insulin stimulus, and reduced reactive hyperaemia. 13 We tested whether the rs753482-A.C variant influences the splicing dynamics of the surrounding exons, thus giving rise to alternative forms of NOS3 with potential pathological consequences. Indeed, we identified three alternatively spliced NOS3 isoforms lacking exon 20 or 21 or both exons. All these alternative splicing events caused a frame shift and a premature stop codon insertion. Interestingly, one of the resulting truncated isoform is stable, forms heterodimers with the full-length eNOS, and exhibits a faulty activation response.
Methods

Patients
The cohort of analysed subjects is aged 30 -75 years inclusive, not affected by T2D. Two hundred and thirty-nine healthy subjects (206 carrying 82A allele and 33 carrying minor allele 82C) and 170 CAD patients (136 carrying 82A allele and 34 minor allele 82C) both underwent metabolic, endothelial, and genetic evaluation. Patients' clinical characteristics and pharmacological treatments are reported in Supplementary material online, Supplementary Data and Table S1 . All subjects were part of a study accepted by the local Ethical Committee and with ClinicalTrial.Gov identifier NCT 00520962, and all patients provided written informed consent before participation, hence conforming to the principles outlined in the Declaration of Helsinki.
Sequence data
The new splicing variants of NOS3 have been submitted to the GenBank database (http://www.ncbi.nlm.nih.gov/genbank/) and assigned the following identifiers: eNOS-delta20, JX853577; eNOS-delta21, JX853578; eNOSdelta20-21, JX853579.
The detailed materials and methods section is included in Supplementary material online, Supplementary Data.
Results
3.1 Healthy subjects and CAD patients show genotype-dependent high fasting NO x levels with blunt response to insulin stimulus
We analysed a cohort of subjects of 239 controls and 170 CAD patients by genotyping rs753482, rs743506, and rs3730010 single nucleotide polymorphisms (SNPs), which map in introns 19, 20, and 21, respectively, of the NOS3 gene.
As a common haplotype block embraces the three SNPs in our cohorts, thus determining the haplotypes rs753482-A_rs743506-A_rs3730010-T and rs753482-C_rs743506-G_rs3730010-C, we consider the rs753482-A.C representative of the haplotype block (nicknamed 82A or 82C; please note that we are considering the NOS3 gene spanning 27 exons, NM_000603.4, thus including the first non-coding exon that was previously disregarded).
We measured fasting and post-glucose load (standard 75 g oral glucose tolerance test, OGTT) nitrite and nitrate (NO x ) concentrations (metabolic end products of NO) and forearm vasodilation after reactive hyperaemia in both healthy subjects and CAD patients. Results are represented in Figure 1 . As expected, healthy and CAD 82A subjects respond positively to oral glucose load by increasing NO x level ( Figure 1A) . Conversely, 82C carriers show a blunt, as for healthy subjects, or negative response, as for CAD patients, who markedly decrease circulating NO x ( Figure 1A) . It is also worth noting a significant difference between 82A and 82C subjects, the latter displaying a sharp increase of fasting NO x levels in both healthy subjects and CAD patients. A similar trend was observed when the same samples were measured by chemiluminescence ( Figure 1B) .
To probe the endothelial function, we evaluated the forearm vasodilation after reactive hyperaemia. Forearm blood flow (FBF) increases as expected after the ischaemic hyperaemia in 82A healthy subjects and CAD patients, whereas it was significantly impaired in 82C carriers ( Figure 1C) . The percentage increase of FBF is significantly reduced in 82C carriers compared with 82A carriers ( Figure 1D) . Similar results were observed measuring post-ischaemic flow-mediated vasodilation (FMD) in the brachial artery in a subgroup of participants ( Figure 1E ).
We obtained a significant correlation between the insulin-induced increased NO x levels during OGTT (120 -0 min) measured by the chemiluminescence method and the percentage change in postischaemic FMD in the brachial artery diameter (R 2 : 0.42, P , 0.0001;
Supplementary material online, Figure S1 ). This might recall the augmented restenosis frequency and increased stenosis length (6.88 + 6.36 mm in 82A vs. 14.72 + 17.81 mm in 82C CAD patients; Supplementary material online, Table S1 ). These experimental findings may indicate a direct link between the presence of the 82C polymorphism and an alteration of NO production in vivo.
Platelets from healthy controls carrying 82C polymorphism have altered eNOS activity
As platelets do express NOS3 and are easily available from peripheral blood, we evaluated the NO x production in platelets derived from 10 healthy subjects, 82A (n ¼ 5) and 82C (n ¼ 5) homozygotes, before and after OGTT. NO production increased significantly after glucose load in 82A subjects ( Figure 1F ). Conversely, we found no difference in 82C allele carriers. When evaluating the differences between pre-and postglucose load, an inversion of genotype-specific result is evident ( Figure 1F ).
NOS3 polymorphism influences mRNA alternative splicing in platelets and endothelial cells
We analysed NOS3 expression and mRNA maturation in platelets and endothelial cells from healthy subjects and CAD patients.
We detected the expected NOS3 full-length transcript in all subjects ( Figures 2B and 3A) . In addition, three novel NOS3 splice variants were revealed in 82C subjects both in platelets and in endothelial cells ( Figures 2B and 3A, respectively) . The same isoforms are present in trace amount in 82A subjects.
In brief, two nested PCRs, PCR A and B, were carried out to amplify the region spanning exons 18-25 and flanking the rs753482 polymorphism (a schema appears in Figure 2A) . We detected the expected band of 458 bp spanning exons 18-21 and an additional lower band (270 bp) in 82C healthy and CAD subjects by PCR A. By testing PCR B, we obtained the expected band (954 bp, exons [19] [20] [21] [22] [23] [24] [25] in all subjects and two lower bands (781 and 593 bp) in 82C healthy and CAD subjects ( Figures 2B and  3A) . PCR product sequencing confirmed that the expected size bands correspond to NOS3 splice isoforms: 270, 781, and 593 bp fragments are NOS3 alternative splicing isoforms corresponding to skipping of exon 20 (D20), exon 21 (D21), and exons 20 and 21 (D20-21), respectively ( Figures 2B and 3A) . All these exon-skipping events generate frameshifts and the introduction of by-chance stop codon. Most importantly, these alternative isoforms lose the C-terminal portion of eNOS protein including a consistent portion of the reductase domain (a schematic representation is shown in Figure 3C ).
A truncated eNOS variant is generated in platelets and endothelial cells of 82C carrying subjects
We then analysed eNOS protein expression. In platelets of 82A subjects including both healthy subjects and CAD patients, antibodies raised against the eNOS N-terminal part decorated a 133 kDa band corresponding to full-length eNOS ( Figure 2C ). This 133 kDa is scarcely Plasmatic NO x levels were measured using the chemiluminescence method in peripheral blood of healthy subjects (24, 82A and 24, 82C), and in CAD patients (24, 82A and 24, 82C) before and after oral glucose load. (C and D) An FBF value before and post-ischaemic stimulus (C ) and percentage change in post-ischaemic FBF (D) in healthy subjects and in CAD patients as in (A); FBF was determined with venous occlusion strain-gauge plethysmography. (E) Percentage in post-ischaemic FMD in healthy subjects (50, 82A and 30, 82C), and in CAD patients (50, 82A and 30, 82C). (F) Intra-platelet NO x levels before and after glucose load (10 healthy subjects: 5, 82A and 5, 82C). Intra-platelets NO x level differences before and after glucose load of 82A and 82C are shown (inset). (A-E) Data represent mean + SD. Statistical significance is indicated (*P , 0.05; **P , 0.01); analysis of variance (ANOVA), followed by Bonferroni's correction for comparison of means. (F ) Paired, one-tailed t-test and inset, unpaired, two-tailed t-test. detectable in platelets from 82C subjects. To be noted, in all 82C subjects, an additional and prevalent band of 92 kDa was observed ( Figure 2C) . A similar lower band was detected in endothelial cells of 82C healthy subjects and CAD patients ( Figure 3B ). In summary, the results indicate that a truncated eNOS variant is generated both in platelets and in endothelial cells of subjects carrying the 82C polymorphism.
82C Allele haplotype is sufficient to drive NOS3 alternative splicing
To confirm the causal link between the 82C polymorphism and the NOS3 alternative splicing found in 82C platelets and endothelial cells, we cloned the genomic region of the NOS3 gene encompassing exons 18-23 into the exon 3 of the alpha-globin gene 14 ( Figure 4A ). The generated chimeric minigene allows isolating and testing the consequence of the presence of the 82C polymorphism on mRNA maturation in foreign context. We obtained two minigene chimeric constructs, pgNOS3_ex18-23_A and pgNOS3_ex18-23_C, expressing alleles 82A and 82C that were transfected into HeLa cells. The relative transcript composition was analysed through reverse transcriptase (RT)-PCRs ( Figure 4A ). We detected the expected transcript including all exons 18-21 (full-length form, FL) and one alternative splice variant skipping exon 20 by PCR I in cells transfected with either plasmids ( Figure 4B ). However, the ratio of FL/D20 was different, being the FL band more in pgNOS3_ex18-23_A transfected cells than in pgNOS3_ex18-23_C ones.
Performing PCR II, we found the expected transcript including all exons 19-23 and two lower bands representing the exon 21 and exons 20-21 skipping in both samples, again with different expression levels ( Figure 4C ). In particular, the expected transcript including all exons 19-23 was the predominant form in cells transfected with pgNOS3_ex18-23_A, while the lower bands, which represent D20 and D20-21 transcripts, were remarkably more represented in cells transfected with pgNOS3_18-23_C. Sequencing of all PCR products confirmed the splice variants as identical to the ones found both in platelets and in endothelial cells. The same results were obtained in HEK293 cell line (data not shown). We conclude that the 82C polymorphism is sufficient to provoke a significant alteration of NOS3 transcript maturation. analysis performed on cDNAs from human endothelial cells of healthy subjects and CAD patients. Ten healthy subjects: 5 carrying allele 82A, 1 -5, and 5 allele 82C, 1 -5; 4 CAD patients: 2 carrying allele 82A, 1 -2, and 2 allele 82C, 1 -2. MK, DNA marker; NTC, no template control; GAPDH was analysed as a housekeeping gene. (B) Western blot using eNOS N-terminal-specific antibodies on total cell lysates from human endothelial cells of subjects as in (A). MW, molecular weight; Hsp60 was analysed as a loading control. Data are representative of three independent experiments. (C ) Schematic representation of the different NOS3 transcripts and the respective protein variants. Full-length NOS3 transcript, NOS3_FL; full-length NOS3 protein, eNOS_FL; NOS3 transcript lacking exon 20 (188 bp), NOS3_D20; corresponding eNOS variant, eNOS_D20; NOS3 transcript lacking exon 21 (173 bp), NOS3_D21; corresponding eNOS variant, eNOS_D21; NOS3 transcript lacking exons 20 and 21 (361 bp), NOS3_D20-21; corresponding eNOS variant, eNOS_D20-21; numbered boxes, NOS3 exons; thin boxes, untranslated regions; dotted boxes, out of frame transcripts and the corresponding translated amino acid sequences; angle line, exon skipping. The alternative splicing of NOS3 transcripts generate frameshifts that introduce premature stop codons: in exon 23 for NOS3_D19 and NOS3_D20 variants, and in exon 21 for NOS3_D19-20 variant. Predicted MWs of eNOS variants are indicated. OXY, eNOS oxygenase domain; CaM, calmodulin-binding site; AE, auto-inhibitory element.
3.6 A stable truncated 82C-specific eNOS isoform is generated by alternative splicing Although three NOS3 alternative transcripts were detected, only an eNOS protein variant of 92 kDa was observed both in platelets and in endothelial cells. To evaluate the in vivo survival of the polypeptides encoded by the D20, D21, and D20 -21 transcripts, we transfected the corresponding cDNA constructs, together with the FL NOS3 cDNA in HeLa cells.
Western blot analysis using eNOS C-terminal antibodies showed a band of 133 kDa in cells transfected with pNOS3_FL expressing the FL eNOS, while no bands were detected in cells transfected with pNOS3_D20, pNOS3_D21, and pNOS3_D20-21 (expressing D20 Figure 5A) .
However, the eNOS N-terminal antibodies detected a band of 92 kDa corresponding to the D20-21 protein variant in pNOS3_D20-21-transfected HeLa cells, corresponding to aa 1-775 of eNOS elongated by 61 spurious amino acids derived by the misreading of 183 nucleotides of exon 22. No bands were detectable in cells transfected with pNOS3_D20 and pNOS3_D21 ( Figure 5B) . When proteasomal degradation was inhibited in transfected cells, the polypeptides corresponding to D20 and D21 transcripts appeared at the predicted size (106 and 107 kDa, respectively) as shown in Figure 5C . These experimental findings indicate that the presence of the 82C polymorphism in intron 19 of NOS3 gene produces a stable truncated D20-21 eNOS protein that lacks a consistent C-terminal portion. Figure 5D ).
The
These results demonstrate that the D20 -21 eNOS variant retains NO synthase activity that is higher than the full-length protein in basal condition, but insensible to intracellular calcium concentration.
3.8 The D20 -21 variant is able to assemble with the full-length eNOS form yielding stable heterodimers with altered activity Since eNOS enzyme is active as a dimer complex, we estimated the ability of the D20-21 variant to assemble into dimers and to assemble with the FL eNOS.
We first evaluated the stability of the eNOS truncated variant by co-transfection of pNOS3_FL with increasing amounts of pNOS3_D20-21 ( Figure 6A) . We found that co-expression of the two proteins results in augmented stability of both proteins, in a dosedependent manner ( Figure 6A) . Interestingly, the co-expression of FL and D20 -21 variant seems to be protective towards proteasome degradation, suggesting that the co-expression of FL and D20-21 eNOS stabilizes the truncated protein, possibly via dimerization, and reduces its degradation ( Figure 6B ).
Since dimerization is essential for the enzymatic activity, we investigated whether D20-21 variant can heterodimerize with full-length eNOS. Cell lysate from HeLa transfected with both pNOS3_FL and pNOS3_D20-21 was immunoprecipitated using C-terminal anti-eNOS antibodies. The pellet was electrophoresis-separated and decorated by the N-terminal anti-eNOS antibodies. We detected the D20-21 variant together with full-length eNOS after immunoprecipitation, demonstrating the presence of a FL-D20-21 heterodimer complex ( Figure 6C ). To verify whether the truncated eNOS variant can also form homodimers, we performed low temperature polyacrylamide gel electrophoresis (LT-PAGE) ( Figure 6D ). As expected most of the FL eNOS not only forms homodimeric complexes, but also D20-21 eNOS is able to homodimerize, though leaving a residual amount of monomer. Finally, by co-expressing FL and D20-21 eNOS proteins, we detected the two homodimers (i.e. FL and D20-21 eNOS) together with the additional heterodimeric complex ( Figure 6D) , which pauperizes the amount of both homodimers.
Enzymatic activity of D20 -21 eNOS
eNOS enzyme activity for the FL and D20 -21 variant is presented in Figure 6E . The FL protein displayed marginal basal activity, which was remarkably increased after Ca 2+ -ionomycin provocation. The D20-21 eNOS basal activity increased accordingly to the augmentation of the truncated eNOS expression (P , 0.01); most interestingly, it failed to respond to intracellular calcium elevation. Conversely, when the D20 -21 variant was co-expressed with FL, basal NO synthesis does not increase proportionally to the truncated protein level. In particular, respect to FL alone, basal activity was 2.42 + 0. 10 Figure 6E ). As expected, Ca 2+ -ionomycin treatment per se results in unaltered FL and D20-21 eNOS stability, as verified by western blot analysis (Supplementary material online, Figure S4 ). Overall, these results consistently resemble those found in 82C healthy and CAD subjects, increased basal enzyme activity and inhibitory response after glucose load.
The D20 -21 eNOS variant displays increased intracellular reactive oxygen species production after stimulation
Decreased NO production could result from eNOS uncoupling, i.e. the NO synthesis activity converts to O 2 −· generation. 15 We thus analysed the intracellular reactive oxygen species (ROS) production using the cell-permeant ROS indicator 5-(and 6-)chloromethyl-2 ′ ,7 ′ -dichlorodihydrofluorescein diacetate, acetyl ester (CM-H 2 DCFDA, DCF for short). HeLa cells were transfected with pNOS3_FL, pNOS3_D20-21, or both, together with a mitochondria-targeted red fluorescent protein as a transfection tracer, and DCF fluorescence was measured by live imaging on single cells. In basal conditions, cells expressing FL, D20-21, or both eNOS variants showed mild but significant increase in DCF signal in comparison with mock-transfected cells ( Figure 6F) . After ionomycin stimulus, we detected a significant increase in ROS production in the presence of FL eNOS that is further augmented by overexpression of the D20 -21 or FL/D20-21 eNOS proteins. Preincubation with the eNOS inhibitor L-NG-nitroarginine methyl ester (L-NAME) blunted DCF fluorescence, indicating the abolition of eNOS- 2 mg, corresponding to 1 : 3 molar ratio) or EV, as indicated. Anti-myc antibodies were used to detect both proteins. FL, p-NOS3_FLmyc; D20 -21, p-NOS3_D20-21myc; EV. Numbers in the low temperature polyacrylamide gel electrophoresis (LT-PAGE) indicate FL eNOSmyc homodimer (1), D20 -21 eNOSmyc monomer (2), D20 -21 eNOSmyc homodimer (3), and FL/D20 -21 eNOSmyc heterodimer (4). Actin was analysed as a loading control. (E) eNOS activity assay on HeLa cells expressing the FL-eNOS and D20-21 splice variant with a constant amount of pNOS3_FL (0.4 mg) and increasing amounts of pNOS3_D20-21, 1 : 1, 1 : 2, and 1 : 3 molar ratio (0.4, 0.8, and 1.2 mg, respectively). Total DNA amount (1.6 mg) was maintained constant adding EV, where necessary. FL, p-NOS3_FL; D20-21, p-NOS3_D20-21; EV, empty vector. White bars, basal state; grey bars, Ca-ionomycin stimulated. Data represent the production of L-citrulline (NO pmol min 21 mg 21 protein) relative to untransfected cells (NT) and are mean + SD of five independent experiments, each biological sample was replicated six times per experiment. Statistical significance is indicated (*P , 0.05; **P , 0.01); ANOVA, followed by Bonferroni's correction for comparison of means. (F) Quantification of intracellular ROS production in HeLa cells expressing FL-eNOS and/or D20 -21 splice variant at 1 : 3 molar ratio as in (E) White bars, basal state; hatched bars, pre-incubated with L-NAME; grey bars, Ca-ionomycin stimulated; grey hatched bars, pre-incubated with L-NAME and Ca -ionomycin stimulated. Data are mean + SE of four independent experiments and are expressed as the percentage of fluorescence relative to EV-transfected cells. Significant differences are indicated by bars (P , 0.01).
dependent ROS production ( Figure 6F) . It is worth noting that upon L-NAME treatment, ROS production diminished in unstimulated cells expressing FL, D20-21, or FL/D20-21 eNOS isoforms, hence underlining that ROS production is intrinsically associated with NO synthesis when eNOS is highly expressed, as previously reported. 16 This result supports the uncoupling state of the stimulated D20-21 eNOS isoform, with an increased ROS production associated with decrease NO synthesis ( Figure 6E ).
Discussion
The mammalian NO synthase is a complex tripartite protein harbouring the oxygenase, the CaM-binding, and the reductase domains. The N-terminal oxygenase domain of eNOS represents the catalytic centre and contains binding sites for haem, arginine, and tetrahydrobiopterin, while the reductase domain (the electron harvesting centre) supports binding sites for FMN, FAD, and NADPH. These two domains are linked by a connecting region where CaM binds (aa 492 -511) and, upon binding, activates the NO synthesis. 17, 18 eNOS is a dimer linked and aligned head-to-head through the oxygenase domain, where electrons are funnelled by the reductase domain of contralateral monomer. The molecular switch resides in the FMN domain, which oscillates from the close to open conformation, according to its vicinity and interaction with the FAD or the oxygenase domain, respectively. The open conformation corresponds to the active NO-synthesizing asset, which couples FMN electrons draining to dioxygen reduction, and finally, NO synthesis. 17, 19 Here, we show data on a novel eNOS isoform, D20-21 eNOS, with altered properties, that originates by alternative splicing, lacks part of the reductase domain, and is present in human platelets and endothelial cells. The alternative splicing event leading to the generation of D20 -21 eNOS is essentially driven by the 82C-specific haplotype. This is not secondary and restricted to the NOS3 genomic locus, since the chimeric construct harbouring the NOS3 genomic portion spanning exons 18 -23 inserted within the globin gene shows that the 82C allele is sufficient to direct the exon 20-21 skipping even outside of its natural genomic context.
As we show, the D20-21 eNOS polypeptide of 92 kDa is quite stable; it interrupts the canonical sequence to aa 775 by adding an unauthentic tail of 61 aa, thus affecting the reductase domain by losing its C-terminal region including FAD and NADPH regulatory domains and the important serine residue 1179, but maintaining the FMN domain. Most importantly, the D20 -21 eNOS displays increased basal eNOS activity in comparison with the full-length protein.
Indeed, evidence on the stability of a truncated eNOS protein with partial deletion of the reductase domain has already been provided. Ghosh et al. 20 showed that synthetic variants of NOS proteins composed of the oxygenase and FMN-binding domains and are stable, dimerize, and synthesize NO with peroxide as the electron donor in vitro. We propose that the higher basal activity of the D20 -21 eNOS results from the lack of two regulatory elements: the connecting loop between FAD and NADPH domains that plays an auto-inhibitory role, 21 and the carboxyl-terminal S1179 that, when phosphorylated, greatly enhances NO synthesis. 22 It is worth noting that transgenic mice expressing a S1179-phosphomimetic form suffer from increased vascular reactivity and improved cerebral blood flow. 23 In addition, the partial deletion of the reductase domain would also decrease the inhibition of basal NO synthesis by caveolin-1. This latter, in fact, interacts with the reductase domain to impede CaM binding and thereby inhibiting NO production. 24 The unexpected competence of NO synthesis of D20 -21 eNOS, lacking the NADPH/FAD domain, might stem from two scenarios.
The electron transfer to the D20-21 oxygenase domain involves unrelated reductase proteins. Interestingly, bacterial NO synthase lacks the reductase domain, but captures adaptable redox partners not normally committed to NO production. 25 Otherwise, alternative redox cellular pathways funnel electrons to FMN, now FMNH 2 or FMNH 2 , and finally to the oxygenase domain.
The production of NO by the D20 -21 eNOS would then be favoured by the lack of inhibitory elements, thus shifting the D20 -21 variant structure to the open conformation displaying the FMN subdomain in close proximity to the oxygenase one. Despite the abovementioned high basal activity, we did not observe any additional increase in NO synthesis by the D20-21 eNOS after calcium-ionomycin stimulus, though the Ca 2+ -CaM-binding site, that physiologically boosts NO synthesis, is still present. This is consequential, in our opinion, to the lack of the C-terminal region including FAD and NADPH domains that fails to provide additional electrons for the dioxygen reduction.
Since we demonstrate that D20-21 eNOS is able to heterodimerize with the full-length eNOS, we investigated the catalytic activity by co-expressing the two isoforms. As shown, D20-21 eNOS exerts a putative modulatory dominant-negative effect by increasing basal NO synthesis and displaying unchanged or negative response to calciumionomycin. Interestingly, we detected an increased production of ROS in ionomycin-stimulated cells when expressing the truncated eNOS variant, both alone and together with FL. Thus, we put forward that the decreased NO synthesis is consequent to enzyme uncoupling. Actually, the flow of electrons within the eNOS dimer is tightly regulated and, if disturbed, the chemical reduction of oxygen and the generation of NO are uncoupled, hence superoxide anions are generated by the oxygenase domain. 26 Therefore, eNOS dimers including the D20-21
variant would shift the balance towards an uncoupled state favouring ROS generation instead of NO synthesis. This result resembles previous findings on artificially truncated eNOS variants 27 and from the short eNOS isoform encoded by exon 1-13 28 that both exert a dominant-negative effect on full-length eNOS NO production.
The presence of the D20-21 eNOS in platelets and endothelial cells strongly associates with the 82C allele to both healthy subjects and CAD patients, though these latter are more frequently 82C carriers. 13 Interestingly, in 82C subjects, we find an increased basal level of NO, which is insensitive to further boost by enhancing insulin levels with OGTT stimulation in platelets. In fact, stimulated insulin receptors on endothelial cells activate the phosphatidylinositol 3-kinase/Akt pathway that, in turns, phosphorylates eNOS at S1179 with the consequent NO release and vasodilation. 29 The lack of the S1179 residue in the D20 -21 eNOS can explain the failure to increase NO release upon insulin stimulation in CAD patients and can be associated with accelerated atherosclerosis and cardiovascular disease. Indeed, the vascular effects of insulin in reducing platelet aggregation are well demonstrated and are attributable to increased synthesis of NO. 30 In addition, reduced platelet function could increase platelets aggregability that mediates intimal thickening, as NO plays an essential role in inhibiting platelet aggregation. 31 Furthermore, FBF after reactive hyperaemia and post-ischaemic FMD in the brachial artery is impaired in both 82C healthy subjects and CAD patients, suggestive of an abnormally responding endothelium, thus mimicking the pharmacological inhibition of NO synthesis. 32 Interestingly, the 50% reduction of post-ischaemic FMD observed in 82C carriers compared with 82A ( Figure 1E ) resembles the mean decrease in postischaemic FMD obtained during intra-arterial infusion of the eNOS inhibitor L-NAME in humans. 33 Our results on CAD patients also support in vivo the role of the eNOS variant in accelerating atherosclerosis and cardiovascular disease and increasing the risk of restenosis/amputation/ulceration/sudden cardiac arrest/death. 34 Pronounced intimal thickening, responsible for the accelerated atherosclerosis and increased restenosis, is likely the result of the impairment of endothelium-dependent NO-mediated relaxation. Other studies have emphasized the importance of microvascular dysfunction in cardiovascular diseases including blunted reactive hyperaemia, 35 also associated with manifest progression of carotid artery atherosclerosis. 36 In conclusion, we demonstrated that NOS3 82A/C polymorphism affects its mRNA maturation, provoking the skipping of exons 20 and 21 and generating a novel and stable isoform of eNOS consistently and physiologically present in endothelial cells and platelets. This truncated eNOS has increase basal NO synthesis activity, fails to respond to calcium -ionomycin and insulin stimulation, and shows a negative dominance on the NO synthesis catalysed by the full-length eNOS. We thus propose that the rs753482-A.C polymorphism acting through the truncated isoform affects the endothelial response not only in CAD, but also in healthy, subjects. Therefore, rs753482-C carriers are proposed as risky subjects for the broad group of disorders originating from dysfunctional or simply affecting the endothelium.
While these data open to new intriguing perspectives in viewing different diseases involving vasculature response to NO, further studies are needed to clarify the molecular mechanisms of action and regulation of D20-21 eNOS both in CAD patients and in 82C healthy subjects, these latter being possibly considered as a new potential class at risk for endothelial dysfunction, early atherosclerosis, and CAD.
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